What a great job by Senior Management, particularly the leadership of

In the third quarter 2014, sales generated in North America reached €26.4 million, up 96.5% year-on-year, driven by the resumption of Increlex® supply in June 2014, the strong 41.7% Somatuline® growth, and the exceptional deliveries made to Galderma in aesthetic medicine. In the first nine months 2014, sales amounted to €57.9 million, up 19.7%, affected by the supply interruption of Increlex® in the first half of the year. Restated for Increlex® supply interruption, sales increased 36.3% in the first nine months. Sales in North America represented 6.0% of consolidated Group sales, compared to 5.4% a year earlier.